Tecarfarin
Anticoagulation in End-Stage Kidney Disease (ESKD) patients with Atrial Fibrillation (AF) and Patients with Left Ventricular Assist Devices (LVADs)
Key Facts
About Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage biotech focused on addressing critical gaps in anticoagulation therapy across acute and chronic settings. Its strategy leverages a differentiated pipeline of three assets targeting high-unmet-need, often orphan, cardiovascular and thrombotic disorders. Key achievements include advancing its lead asset, CAD-1005 for HIT, to Phase 3 readiness with Orphan Drug and Fast Track designations, and positioning tecarfarin for Phase 3 trials in end-stage kidney disease and LVAD patients. The company aims to deliver targeted therapies where current standards are inadequate or carry significant risk.
View full company profile